A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer

Andrew Weickhardt, Robert Doebele, Ana Oton, Janice Lettieri, Delee Maxson, Michele Reynolds, Amy Brown, Mary K. Jackson, Grace Dy, Araba Adjei, Gerald Fetterly, Xian Lu, Wilbur Franklin, Marileila Varella-Garcia, Fred R. Hirsch, Murry W. Wynes, Hagop Youssoufian, Alex Adjei, D. Ross Camidge

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences